Mitiglinide

Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide can be used for the research of type 2 diabetes[1][2].

Product Specifications

CAS Number

[145375-43-5]

Product Name Alternative

KAD-1229 (free acid anhydrous) ; S21403 (free acid anhydrous)

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/mitiglinide.html

Solubility

10 mM in DMSO

Smiles

O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@@H](C(O)=O)CC3=CC=CC=C3

Molecular Formula

C19H25NO3

Molecular Weight

315.41

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.